Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Common Stock
TARA | US
2.01
USD0.10
5.24%
TARA | US
About Common Stock
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
21/10/2024
Close
2.01
Open
1.95
High
2.19
Low
1.87
Protara Therapeutics Inc. a clinical-stage biopharmaceutical company engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002 an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics Inc. and changed its name to Protara Therapeutics Inc. in May 2020. The company is headquartered in New York New York.
View LessTARA | US
Risk
57.0
Sharpe
0.12
Luna's Score
52/100
Recommendation
Hold
Luna says (TARA | US)
What's Working
Strength based on increasing price with high volume
High Current Volume and Positive 1-Day Return
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
What's not Working
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
62.5%1 month
57.0%3 months
53.9%6 months
68.4%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
0.42
Debt to equity
0.05
Debt to assets
0.05
Ent. to EBITDA
0.74
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-43.90M
MarketCap
41.47M
MarketCap(USD)
41.47M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-45.91
Short ratio
13.38
Short perc.
13.83
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Range10D
0.59
Range1M
0.59
Range3M
0.85
Volumes: Market Activity
Rel. volume
4.41
Price X volume
1.34M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 0.74 | 0.53 | Expensive |
| Ent. to Revenue | - | 3,967.00 | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 0.42 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 53.92 | 72.80 | Lower Risk |
| Debt to Equity | 0.05 | -1.23 | Expensive |
| Debt to Assets | 0.05 | 0.25 | Cheaper |
| Market Cap | 41.47M | 3.66B | Emerging |
